Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health.
COVID
Cardiometabolic
Diabetes
Inflammation
Molecular
Journal
Biochimica et biophysica acta. Molecular basis of disease
ISSN: 1879-260X
Titre abrégé: Biochim Biophys Acta Mol Basis Dis
Pays: Netherlands
ID NLM: 101731730
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
received:
08
08
2022
revised:
03
09
2022
accepted:
21
09
2022
pubmed:
30
9
2022
medline:
19
10
2022
entrez:
29
9
2022
Statut:
ppublish
Résumé
Obesity, type 2 diabetes (T2DM), hypertension (HTN), and Cardiovascular Disease (CVD) often cluster together as "Cardiometabolic Disease" (CMD). Just under 50% of patients with CMD increased the risk of morbidity and mortality right from the beginning of the COVID-19 pandemic as it has been reported in most countries affected by the SARS-CoV2 virus. One of the pathophysiological hallmarks of COVID-19 is the overactivation of the immune system with a prominent IL-6 response, resulting in severe and systemic damage involving also cytokines such as IL2, IL4, IL8, IL10, and interferon-gamma were considered strong predictors of COVID-19 severity. Thus, in this mini-review, we try to describe the inflammatory state, the alteration of the adipokine profile, and cytokine production in the obese state of infected and not infected patients by SARS-CoV2 with the final aim to find possible influences of COVID-19 on CMD and CVD. The immunological-based discussion of the molecular processes could inspire the study of promising targets for managing CMD patients and its complications during COVID-19.
Identifiants
pubmed: 36174875
pii: S0925-4439(22)00230-7
doi: 10.1016/j.bbadis.2022.166559
pmc: PMC9510069
pii:
doi:
Substances chimiques
Adipokines
0
Cytokines
0
Interleukin-2
0
Interleukin-6
0
Interleukin-8
0
RNA, Viral
0
Interleukin-10
130068-27-8
Interleukin-4
207137-56-2
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
166559Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: None reports was provided by none. None reports a relationship with none that includes: None has patent pending to none. None.
Références
J Clin Med. 2021 May 01;10(9):
pubmed: 34062770
Front Immunol. 2022 May 18;13:894470
pubmed: 35663992
Front Med (Lausanne). 2021 Mar 18;8:620990
pubmed: 33816521
Glob Heart. 2022 Jan 12;17(1):2
pubmed: 35174043
Front Pharmacol. 2021 Apr 29;12:654425
pubmed: 33995071
Theranostics. 2021 Jul 13;11(17):8234-8253
pubmed: 34373739
Arq Bras Cardiol. 2020 May 11;114(5):805-816
pubmed: 32401847
Obesity (Silver Spring). 2020 Jul;28(7):1191-1194
pubmed: 32314868
Int J Obes (Lond). 2021 Sep;45(9):2028-2037
pubmed: 34112941
Cells. 2022 Feb 04;11(3):
pubmed: 35159352
J Diabetes Complications. 2021 Mar;35(3):107817
pubmed: 33358523
J Pers Med. 2022 Mar 03;12(3):
pubmed: 35330391
Diabetes Res Clin Pract. 2020 Nov;169:108521
pubmed: 33096190
Sci Rep. 2021 Nov 2;11(1):21514
pubmed: 34728695
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Epidemiol Infect. 2021 Jan 05;149:e144
pubmed: 33397542
Lancet Glob Health. 2020 Aug;8(8):e1003-e1017
pubmed: 32553130
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Eur J Med Res. 2020 Dec 2;25(1):64
pubmed: 33267871
Heliyon. 2020 Aug;6(8):e04696
pubmed: 32844126
Cell Mol Immunol. 2021 Oct;18(10):2457-2459
pubmed: 34465884
Mediators Inflamm. 2019 Apr 28;2019:7538071
pubmed: 31182932
Prim Care Diabetes. 2021 Feb;15(1):194
pubmed: 32900656
Arch Med Sci. 2020 Jun 27;17(2):275-284
pubmed: 33747262
Arch Med Sci. 2021 Mar 18;17(3):818-822
pubmed: 34025853
J Biol Chem. 2022 Mar;298(3):101695
pubmed: 35143839
Eur Respir J. 2020 Jun 4;55(6):
pubmed: 32350105
Int J Obes (Lond). 2022 Jul;46(7):1254-1261
pubmed: 35393519
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Int J Obes (Lond). 2020 Sep;44(9):1810-1817
pubmed: 32647360
N Engl J Med. 2020 Feb 6;382(6):545-553
pubmed: 32023374
Nat Med. 2019 Nov;25(11):1644-1646
pubmed: 31700172
Obes Facts. 2020;13(4):430-438
pubmed: 32659766
Diabetes Ther. 2022 Oct;13(10):1723-1736
pubmed: 36030317
J Physiol Biochem. 2022 Aug;78(3):581-591
pubmed: 35316507
Front Immunol. 2021 Jun 18;12:649359
pubmed: 34220807
Int J Obes (Lond). 2020 Aug;44(8):1800-1802
pubmed: 32514077
Life Sci. 2020 Oct 1;258:118167
pubmed: 32735885
Eur Heart J. 2022 Mar 14;43(11):1033-1058
pubmed: 34791157
PLoS One. 2020 Aug 25;15(8):e0237974
pubmed: 32841271
JAMA Cardiol. 2020 Nov 1;5(11):1281-1285
pubmed: 32730555
ERJ Open Res. 2021 Aug 02;7(3):
pubmed: 34350288
Cytokine Growth Factor Rev. 2020 Jun;53:38-42
pubmed: 32360420
Int J Mol Sci. 2021 Nov 03;22(21):
pubmed: 34769350
Neurosci Res. 2020 Sep;158:1-5
pubmed: 32628969
Signal Transduct Target Ther. 2020 May 29;5(1):84
pubmed: 32467561
Int J Clin Pract. 2021 Feb;75(2):e13666
pubmed: 32770758
Lancet Respir Med. 2020 Mar;8(3):267-276
pubmed: 32043986
Diabetes Metab. 2021 Nov;47(6):101268
pubmed: 34333093
J Cardiovasc Pharmacol. 2021 Jul 1;78(1):e1-e2
pubmed: 34173808
Brain Sci. 2021 Apr 02;11(4):
pubmed: 33918426
Int J Med Sci. 2022 Jan 24;19(2):402-415
pubmed: 35165525
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Med Virol. 2020 Oct;92(10):2105-2113
pubmed: 32383269
Metab Syndr Relat Disord. 2020 May;18(4):173-175
pubmed: 32271125
J Diabetes Complications. 2021 Feb;35(2):107809
pubmed: 33288414
Diabetes Obes Metab. 2021 Mar;23(3):870-874
pubmed: 33245182
J Diabetes Complications. 2021 Dec;35(12):108054
pubmed: 34600823
Diabetes Res Clin Pract. 2020 May;163:108151
pubmed: 32305399
Int J Mol Sci. 2021 May 16;22(10):
pubmed: 34065735
J Med Virol. 2021 Dec;93(12):6634-6640
pubmed: 34314067
Cell Death Discov. 2019 Jun 5;5:101
pubmed: 31231549
Obes Rev. 2020 Nov;21(11):e13128
pubmed: 32845580
Front Cardiovasc Med. 2021 Dec 15;8:787761
pubmed: 34977193
Rev Med Virol. 2020 Nov;30(6):1-9
pubmed: 32845568
Sci Rep. 2021 Feb 3;11(1):2941
pubmed: 33536486
Circulation. 2020 Sep 22;142(12):1176-1189
pubmed: 32755393
Int J Obes (Lond). 2021 Sep;45(9):2126-2131
pubmed: 34059786
Cell. 2021 Jan 7;184(1):149-168.e17
pubmed: 33278357
Obesity (Silver Spring). 2021 Apr;29(4):645-653
pubmed: 33270351
Trends Immunol. 2019 Sep;40(9):857-872
pubmed: 31399336
Scand J Immunol. 2021 Feb;93(2):e12960
pubmed: 32797724
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093